Search results for "mass [excited state]"

showing 10 items of 5250 documents

Inhibition of human monoamine oxidase A and B by flavonoids isolated from two Algerian medicinal plants

2017

Abstract Background Monoamine oxidases (MAOs) are outer mitochondrial membrane flavoenzymes. They catalyze the oxidative deamination of a variety of neurotransmitters. MAO-A and MAO-B may be considered as targets for inhibitors to treat neurodegenerative diseases and depression and for managing symptoms associated with Parkinson's and Alzheimer's diseases. Purpose The objective was to evaluate the inhibitory effect of Hypericum afrum and Cytisus villosus against MAO-A and B and to isolate the compounds responsible for the MAO-inhibitory activity. Methods The inhibitory effect of extracts and purified constituents of H. afrum and C. villosus were investigated in vitro using recombinant human…

0301 basic medicineMonoamine Oxidase InhibitorsMonoamine oxidaseDrug Evaluation PreclinicalPharmaceutical ScienceGenisteinMixed inhibitionArticleMass SpectrometryInhibitory Concentration 5003 medical and health scienceschemistry.chemical_compoundDrug DiscoveryHumansChrysinMonoamine OxidaseIC50CytisusFlavonoidsPharmacologyPlants MedicinalMolecular Docking Simulation030104 developmental biologyComplementary and alternative medicinechemistryBiochemistryDocking (molecular)AlgeriaMolecular MedicineQuercetinMyricetinQuercetinHypericumPhytomedicine
researchProduct

2016

AbstractDespite the high global prevalence of dry eye syndrome (DES), the fundamental processes underlying this pathology remain largely unexplored. Therefore, this study endeavoured to investigate in-depth the tear proteome of DES patients employing the mass spectrometry (MS)-based proteomic strategies. Eighty patients were recruited and subdivided into three major DES subgroups, which are the aqueous-deficient (DRYaq), evaporative (DRYlip) and a combination of the two (DRYaqlip), as well as healthy subjects (CTRL). Discovery proteomics strategy was employed to identify large number of significantly differentially expressed tear proteins in DRYlip vs. CTRL, DRYaq vs. CTRL and DRYaqlip vs. …

0301 basic medicineMultidisciplinaryCase-control studyBiologyTandem mass spectrometryProteomicsS100A9S100A803 medical and health sciences030104 developmental biologyImmune systemProteomeImmunologyTearsScientific Reports
researchProduct

Peptide Processing Is Critical for T-Cell Memory Inflation and May Be Optimized to Improve Immune Protection by CMV-Based Vaccine Vectors.

2016

Cytomegalovirus (CMV) elicits long-term T-cell immunity of unparalleled strength, which has allowed the development of highly protective CMV-based vaccine vectors. Counterintuitively, experimental vaccines encoding a single MHC-I restricted epitope offered better immune protection than those expressing entire proteins, including the same epitope. To clarify this conundrum, we generated recombinant murine CMVs (MCMVs) encoding well-characterized MHC-I epitopes at different positions within viral genes and observed strong immune responses and protection against viruses and tumor growth when the epitopes were expressed at the protein C-terminus. We used the M45-encoded conventional epitope HGI…

0301 basic medicineMuromegalovirusEpitopes T-LymphocyteCD8-Positive T-LymphocytesLymphocyte ActivationPathology and Laboratory MedicineBiochemistryEpitopeMass SpectrometryMiceWhite Blood Cells0302 clinical medicineAnimal CellsMedicine and Health SciencesCytotoxic T celllcsh:QH301-705.5Antigens ViralImmune ResponseStainingVaccines SyntheticbiologyT CellsCell StainingHerpesviridae InfectionsFlow CytometryRecombinant Proteins3. Good healthmedicine.anatomical_structureMedical MicrobiologyViral PathogensVirusesHuman CytomegalovirusCellular TypesPathogensResearch Articlelcsh:Immunologic diseases. AllergyHerpesvirusesT cellImmune CellsAntigen presentationImmunologyCytotoxic T cellsMajor histocompatibility complexResearch and Analysis MethodsMicrobiology03 medical and health sciencesViral ProteinsImmune systemAntigenVirologyGeneticsmedicineAnimalsAntigen-presenting cellMolecular Biology TechniquesMolecular BiologyMicrobial PathogensBlood CellsImmunodominant EpitopesOrganismsBiology and Life SciencesProteinsViral VaccinesCell BiologyVirology030104 developmental biologylcsh:Biology (General)Specimen Preparation and Treatmentbiology.proteinMutagenesis Site-DirectedParasitologylcsh:RC581-607PeptidesDNA virusesImmunologic Memory030215 immunologyChromatography LiquidCloningPLoS pathogens
researchProduct

An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques

2016

Chronic unresolved inflammation plays a causal role in the development of advanced atherosclerosis, but the mechanisms that prevent resolution in atherosclerosis remain unclear. Here, we use targeted mass spectrometry to identify specialized pro-resolving lipid mediators (SPM) in histologically-defined stable and vulnerable regions of human carotid atherosclerotic plaques. The levels of SPMs, particularly resolvin D1 (RvD1), and the ratio of SPMs to pro-inflammatory leukotriene B4 (LTB4), are significantly decreased in the vulnerable regions. SPMs are also decreased in advanced plaques of fat-fed Ldlr−/− mice. Administration of RvD1 to these mice during plaque progression restores the RvD1:…

0301 basic medicineNecrosisLeukotriene B4ScienceGeneral Physics and AstronomyInflammationmedicine.disease_causeArticleGeneral Biochemistry Genetics and Molecular Biology03 medical and health scienceschemistry.chemical_compoundAtherosclerosis--EtiologymedicineCarotid artery--DiseasesEfferocytosisInflammationAtherosclerotic plaqueMultidisciplinarybusiness.industryQGeneral ChemistryLipid signalingAtherosclerosisResolvin d1030104 developmental biologyTargeted mass spectrometrychemistryCancer researchMedicinemedicine.symptombusinessOxidative stressNature Communications
researchProduct

The Volatilomic Footprints of Human HGC-27 and CLS-145 Gastric Cancer Cell Lines

2021

The presence of certain volatile biomarkers in the breath of patients with gastric cancer has been reported by several studies; however, the origin of these compounds remains controversial. In vitro studies, involving gastric cancer cells may address this problem and aid in revealing the biochemical pathways underlying the production and metabolism of gastric cancer volatile indicators. Gas chromatography with mass spectrometric detection, coupled with headspace needle trap extraction as the pre-concentration technique, has been applied to map the volatilomic footprints of human HGC-27 and CLS-145 gastric cancer cell lines and normal Human Stomach Epithelial Cells (HSEC). In total, 27 volat…

0301 basic medicineNonanalEthyl acetateHexanalBiochemistry Genetics and Molecular Biology (miscellaneous)Biochemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicinevolatile organic compoundsMolecular Bioscienceslcsh:QH301-705.5Molecular BiologyOriginal ResearchChemistrygastric cancerMetabolismCLS-145HGC-27Heptanal030104 developmental biologychemical footprintBiochemistrylcsh:Biology (General)Cell culture030220 oncology & carcinogenesisCancer cellGas chromatography–mass spectrometryGC-MSFrontiers in Molecular Biosciences
researchProduct

Discovery of a Pederin Family Compound in a Nonsymbiotic Bloom-Forming Cyanobacterium

2018

The pederin family includes a number of bioactive compounds isolated from symbiotic organisms of diverse evolutionary origin. Pederin is linked to beetle-induced dermatitis in humans, and pederin family members possess potent antitumor activity caused by selective inhibition of the eukaryotic ribosome. Their biosynthesis is accomplished by a polyketide/nonribosomal peptide synthetase machinery employing an unusual trans-acyltransferase mechanism. Here, we report a novel pederin type compound, cusperin, from the free-living cyanobacterium Cuspidothrix issatschenkoi (earlier Aphanizomenon). The chemical structure of cusperin is similar to that of nosperin recently isolated from the lichen cya…

0301 basic medicineNostocSpectrometry Mass Electrospray IonizationMagnetic Resonance SpectroscopyGENE-CLUSTERPAEDERUSpederinsPederinCyanobacteriaBiochemistry03 medical and health scienceschemistry.chemical_compoundPolyketideBiosynthesisNonribosomal peptideTandem Mass SpectrometryCHEMISTRYGene clusterBACTERIAL SYMBIONTBIOSYNTHESISPeptide SynthasesSymbiosissyanobakteeritta116chemistry.chemical_classificationbioactive compoundsbiologybioaktiiviset yhdisteetta1182General Medicinebiology.organism_classificationluonnonaineetnaturally occurring substancesamidesPOLYKETIDE SYNTHASES030104 developmental biologychemistryBiochemistryGenes BacterialMultigene FamilyPolyketidesamiditCyanobiontMolecular Medicine1182 Biochemistry cell and molecular biologyEukaryotic Ribosome
researchProduct

Toxicity reduction of ochratoxin A by lactic acid bacteria.

2017

Abstract Ochratoxin A (OTA) is a mycotoxin produced by the metabolism of fungus belonging to the genus Aspergillus and Penicillium. In this paper we report, the capacity of different cultures of lactic acid bacteria (LAB) to degrade OTA present in MRS broth at both pH 3.5 and 6.5. A study of OTA reduction during gastrointestinal digestion carried out with the LAB was also performed. Taking into account the two reduction mechanisms of OTA studied in this work as the enzymatic one and the adsorption on the cell wall, as well as at pH 3.5 and 6.5 the reduction values of OTA were in a range of 30–99%, being the strains with greater reduction (97% and 95%) Lb. rhamnosus CECT 278T and Lb. plantar…

0301 basic medicineOchratoxin APhenylalanine030106 microbiologyPhenylalanineFood ContaminationToxicologyMass Spectrometry03 medical and health scienceschemistry.chemical_compound0404 agricultural biotechnologyCell WallLactobacillalesHumansFood scienceMycotoxinAspergillusbiologyfood and beverages04 agricultural and veterinary sciencesGeneral MedicineMetabolismReference Standardsbiology.organism_classification040401 food scienceOchratoxinsLactic acidCulture MediaGastrointestinal TractchemistryPenicilliumInactivation MetabolicAdsorptionBacteriaFood ScienceChromatography LiquidFood and chemical toxicology : an international journal published for the British Industrial Biological Research Association
researchProduct

Circulating miR-130a, miR-27b, and miR-210 in Patients With Peripheral Artery Disease and Their Potential Relationship With Oxidative Stress: A Pilot…

2016

Some emerging risk factors such as oxidative stress biomarkers and microRNAs (miRs) may add additional value to the established risk factors for peripheral artery disease (PAD). We enrolled 27 patients with PAD and 27 age-matched controls. We examined the levels of a series of miRs (miR-130a, miR-27b, and miR-210) in serum samples. The level of well-established oxidative stress biomarkers, such as lipid hydroperoxides, isoprostanes, hemeoxygenase-1 (HO-1) and reduced glutathione, was also measured in plasma and their relationship with the miRs was determined. Levels of miR-130a, miR-27b, and miR-210 were significantly increased in patients with PAD when compared to the controls. The level …

0301 basic medicineOncologyMalemedicine.medical_specialtyLipid PeroxidesStatistics as TopicPilot ProjectsDisease030204 cardiovascular system & hematologyIsoprostanesmedicine.disease_cause03 medical and health scienceschemistry.chemical_compoundPeripheral Arterial Disease0302 clinical medicineIsoprostaneRisk FactorsInternal medicinemicroRNAmedicineHumansPilot ProjectIn patientAgedoxidative streHeme OxygenasemicroRNALipid Peroxidebusiness.industryRisk FactorBiomarkerGlutathioneMiddle AgedGlutathioneHeme oxygenaseMicroRNAsOxidative Stress030104 developmental biologychemistryBiomarker (medicine)FemaleCardiology and Cardiovascular MedicinebusinessBody mass indexOxidative stressBiomarkersHeme Oxygenase-1Human
researchProduct

Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence

2020

Body mass index (BMI) is a main indicator of obesity and its association with breast cancer is well established. However, little is known in the metastatic setting, especially in HER2-positive patients. We assessed the influence of BMI on clinical outcomes of patients treated with pertuzumab and/or trastuzumab emtansine (T-DM1) for HER2+ metastatic breast cancer (mBC). BMI was addressed as a categorical variable, being classified on the basis of the following ranges, that is, 18.5-24.9, 25-29.9, and 30.0-34.9, namely, normal weight, overweight, and Class I obesity. The outcomes chosen were progression-free survival to first-line chemotherapy (PFS1) and overall survival (OS). Overall (N = 70…

0301 basic medicineOncologyPhysiologyReceptor ErbB-2Clinical BiochemistryAdo-Trastuzumab EmtansineSettore MED/06body mass index; HER2-positive metastatic breast cancer; pertuzumab; trastuzumab emtansinechemistry.chemical_compound0302 clinical medicineAntineoplastic Agents ImmunologicalAged 80 and overeducation.field_of_studyUnivariate analysisMiddle AgedMetastatic breast cancerProgression-Free SurvivalQuartile030220 oncology & carcinogenesisHER2-positive metastatic breast cancerDisease ProgressionFemalePertuzumabmedicine.drugAdultmedicine.medical_specialtyPopulationBreast Neoplasmsbody mass indexAntibodies Monoclonal Humanized03 medical and health sciencesBreast cancerSettore MED/04 - PATOLOGIA GENERALEpertuzumabInternal medicinemedicineHumansObesityeducationAgedtrastuzumab emtansinebusiness.industrynutritional and metabolic diseasesCell BiologyOverweightmedicine.disease030104 developmental biologychemistryTrastuzumab emtansineMED/06 - ONCOLOGIA MEDICAbusinessBody mass index
researchProduct

Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized t…

2019

Highlights • Hormonal receptors positive breast tumor and prostate cancer are managed with endocrine therapies. • Endocrine therapies designed for breast and prostate cancer are often associated to serious adverse skeletal related events, such fractures. • Denosumab is a monoclonal anti-body binding RANKL which acts as inhibitor of osteoclasts activity, thus increasing bone mass. • Denosumab was showed to strongly prevent hormonal therapies-related skeletal issues. • Denosumab administration results safe in bone mass increase and reduction of fractures risk.

0301 basic medicineOncologyRCTs randomized clinical trialrandomized clinical trialslcsh:Diseases of the musculoskeletal systemSettore MED/06 - Oncologia MedicaOsteoporosisBMD bone mass densityReview Articleandrogen deprivation therapyADTlaw.inventionAndrogen deprivation therapyProstate cancerhazard ratio0302 clinical medicineRandomized controlled triallawHRMedicineBreastSAEsCancerProstateRANKLCIMD mean differencelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensRCTs randomized clinical trialsDenosumabOncology030220 oncology & carcinogenesisSAEs serious adverse eventsDenosumabmean differencemedicine.drugmedicine.medical_specialtylcsh:RC254-28203 medical and health sciencesBreast cancerRANKL receptor activator of nuclear factor-kB ligandBMDInternal medicineAdverse effectADT androgen deprivation therapyRCTsbusiness.industryMDmedicine.diseaseHR hazard ratioHormonereceptor activator of nuclear factor-kB ligandDiscontinuationCI confidence interval030104 developmental biologyFractureconfidence intervalADT androgen deprivation therapy; BMD bone mass density; Breast; CI confidence interval; Cancer; Denosumab; Fracture; HR hazard ratio; Hormone; MD mean difference; Prostate; RANKL receptor activator of nuclear factor-kB ligand; RCTs randomized clinical trials; SAEs serious adverse eventsserious adverse eventsbone mass densitylcsh:RC925-935businessJournal of Bone Oncology
researchProduct